BLCM - ベリカム・ファ―マシュ―ティカルズ （Bellicum Pharmaceuticals Inc.） ベリカム・ファ―マシュ―ティカルズBLCMのチャート
BLCMの企業情報
| symbol | BLCM |
|---|---|
| 会社名 | Bellicum Pharmaceuticals Inc （ベリカム・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ベリカム・ファーマスーティカルズ(Bellicum Pharmaceuticals Inc)は臨床段階のバイオ医薬品会社である。同社は血液癌、固形癌とオーファン遺伝性血液疾患等の癌の細胞免疫療法の発見・開発に従事する。同社は二量体化学誘導(CID)技術プラットフォームによって、免疫系のコンポーネントの設計・制御を行う。同社は造血幹細胞移植(HSCT)、キメラ抗原レセプター(CAR)T細胞療法とT細胞レセプター(TCR)細胞療法等の細胞免疫療法分野の次世代製品候補の開発を行う。同社の製品はBPX-501、BPX-601、BPX-701を含む。CIDベースの技術はCaspaCIDe、GoCAR-Tを含む。同社は米国とヨーロッパにある白血病、リンパ腫と遺伝性血液疾患を有する成人・小児患者の第一または第二臨床試験への評価を行う。 ベリカム・ファ―マシュ―ティカルズは、米国の新興バイオ医薬品会社。癌の免疫療法やワクチンの発見や開発に注力する。また、｢CaspaCIDe｣という細胞のアポト―シス(細胞死)を誘導する仕組みを利用した自殺遺伝子に関する技術を保有する。本社は、テキサス州ヒュ―ストン。 Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company's next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum's GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. |
| 本社所在地 | 2130 W. Holcombe Blvd. Ste. 800 Houston TX 77030 USA |
| 代表者氏名 | James Farrell Brown ジェームスファレルブラウン |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 832-384-1100 |
| 設立年月日 | 38169 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 137人 |
| url | www.bellicum.com |
| nasdaq_url | https://www.nasdaq.com/symbol/blcm |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -82.70400 |
| 終値（lastsale） | 5.8 |
| 時価総額（marketcap） | 251424234.8 |
| 時価総額 | 時価総額（百万ドル） 296.70810 |
| 売上高 | 売上高（百万ドル） 0.57300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 202.86210 |
| 当期純利益 | 当期純利益（百万ドル） -92.36400 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Bellicum Pharmaceuticals Inc revenues increased from $128K to $516K. Net loss increased 1% to $47M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research_Development Expense increase of 5% to $31.7M (expense) Stock-based Compensation in SGA increase of 11% to $3.9M (expense). |
BLCMのテクニカル分析
BLCMのニュース
Bellicum Pharmaceuticals: Q1 Earnings Snapshot 2022/05/12 21:02:27 mySA
HOUSTON (AP) _ Bellicum Pharmacueticals Inc. (BLCM) on Thursday reported a loss of $7.6 million in its first quarter. The Houston-based company said it had a loss of 25 cents per share. In the final minutes of trading on Thursday, the company''s shares hit $1.43. A year ago, they were trading at $2.95. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BLCM at https://www.zacks.com/ap/BLCM
Bellicum Pharmaceuticals GAAP EPS of -$0.25 beats by $0.42 (NASDAQ:BLCM) 2022/05/12 20:45:37 Seeking Alpha
Bellicum Pharmaceuticals press release (BLCM): Q1 GAAP EPS of -$0.25 beats by $0.42.Bellicum reported cash and cash equivalents and restricted cash totaling $41.3 million as of March…
Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update 2022/05/12 20:05:00 GlobeNewswire
HOUSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the first quarter 2022 and provided an operational update.
Bellicum Pharmaceuticals (NASDAQ:BLCM) Shares Pass Below Fifty Day Moving Average of $1.95 2021/12/22 08:12:42 ETF Daily News
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) shares passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.95 and traded as low as $1.67. Bellicum Pharmaceuticals shares last traded at $1.69, with a volume of 149,038 shares traded. The company has a market cap of $14.19 [] The post Bellicum Pharmaceuticals (NASDAQ:BLCM) Shares Pass Below Fifty Day Moving Average of $1.95 appeared first on ETF Daily News .
Bellicum Regains Compliance with Nasdaq Continued Listing Requirements 2021/12/13 21:05:00 Intrado Digital Media
HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has received a letter from the Listing Qualifications Hearings Department of The Nasdaq Stock Market LLC notifying the company that it has regained compliance with Listing Rule 5550(b)(1), which requires stockholders equity of at least $2.5 million for continued listing of the companys common stock. Accordingly, the Company is now in compliance with the continued listing requirements of The Nasdaq Capital Market. The notification follows the companys recent completion of its private placement of equity securities for gross proceeds of approximately $35.0 million, before deducting placement agent commissions and offering expenses payable by the Company.
Bellicum Pharmaceuticals: Q1 Earnings Snapshot 2022/05/12 21:02:27 mySA
HOUSTON (AP) _ Bellicum Pharmacueticals Inc. (BLCM) on Thursday reported a loss of $7.6 million in its first quarter. The Houston-based company said it had a loss of 25 cents per share. In the final minutes of trading on Thursday, the company''s shares hit $1.43. A year ago, they were trading at $2.95. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BLCM at https://www.zacks.com/ap/BLCM
Bellicum Pharmaceuticals GAAP EPS of -$0.25 beats by $0.42 (NASDAQ:BLCM) 2022/05/12 20:45:37 Seeking Alpha
Bellicum Pharmaceuticals press release (BLCM): Q1 GAAP EPS of -$0.25 beats by $0.42.Bellicum reported cash and cash equivalents and restricted cash totaling $41.3 million as of March…
Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update 2022/05/12 20:05:00 GlobeNewswire
HOUSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial results for the first quarter 2022 and provided an operational update.
Bellicum Pharmaceuticals (NASDAQ:BLCM) Shares Pass Below Fifty Day Moving Average of $1.95 2021/12/22 08:12:42 ETF Daily News
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) shares passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.95 and traded as low as $1.67. Bellicum Pharmaceuticals shares last traded at $1.69, with a volume of 149,038 shares traded. The company has a market cap of $14.19 [] The post Bellicum Pharmaceuticals (NASDAQ:BLCM) Shares Pass Below Fifty Day Moving Average of $1.95 appeared first on ETF Daily News .
Bellicum Regains Compliance with Nasdaq Continued Listing Requirements 2021/12/13 21:05:00 Intrado Digital Media
HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has received a letter from the Listing Qualifications Hearings Department of The Nasdaq Stock Market LLC notifying the company that it has regained compliance with Listing Rule 5550(b)(1), which requires stockholders equity of at least $2.5 million for continued listing of the companys common stock. Accordingly, the Company is now in compliance with the continued listing requirements of The Nasdaq Capital Market. The notification follows the companys recent completion of its private placement of equity securities for gross proceeds of approximately $35.0 million, before deducting placement agent commissions and offering expenses payable by the Company.
Bellicum Pharmaceuticals (NASDAQ:BLCM) Shares Pass Below Fifty Day Moving Average of $1.95 2021/12/22 08:12:42 ETF Daily News
Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) shares passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $1.95 and traded as low as $1.67. Bellicum Pharmaceuticals shares last traded at $1.69, with a volume of 149,038 shares traded. The company has a market cap of $14.19 [] The post Bellicum Pharmaceuticals (NASDAQ:BLCM) Shares Pass Below Fifty Day Moving Average of $1.95 appeared first on ETF Daily News .
Bellicum Regains Compliance with Nasdaq Continued Listing Requirements 2021/12/13 21:05:00 Intrado Digital Media
HOUSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that it has received a letter from the Listing Qualifications Hearings Department of The Nasdaq Stock Market LLC notifying the company that it has regained compliance with Listing Rule 5550(b)(1), which requires stockholders equity of at least $2.5 million for continued listing of the companys common stock. Accordingly, the Company is now in compliance with the continued listing requirements of The Nasdaq Capital Market. The notification follows the companys recent completion of its private placement of equity securities for gross proceeds of approximately $35.0 million, before deducting placement agent commissions and offering expenses payable by the Company.
Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM): This Is The Year For Success Over The Next Few Months 2021/12/06 21:00:00 Marketing Sentinel
In todays recent session, 0.77 million Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) shares changed hands as the companys beta touched 1.52. With the companys per share price at $1.53 changed hands at -$0.16 or -9.47% during last session, the market valuation stood at $14.91M. BLCMs last price was a discount, traded about -432.68% off its 52-week high Bellicum Pharmaceuticals Inc. (NASDAQ: BLCM): This Is The Year For Success Over The Next Few Months Read More »
Bellicum Reports Positive Interim Data From Phase 1/2 GoCAR-T Trials - Quick Facts 2021/12/06 13:10:39 Business Insider Markets
(RTTNews) - Bellicum Pharmaceuticals, Inc. (BLCM) reported positive interim data from ongoing phase 1/2 GoCAR-T clinical trials, including a confirmed partial response in the first cohort of mCRPC patients treated in the clinical trial for BPX-601. Charity Scripture, Chief Development Officer of Bellicum, said: "The early clinical activity we
Squarepoint Ops LLC Sells 11,588 Shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) 2021/11/27 10:22:41 Dakota Financial News
Squarepoint Ops LLC cut its stake in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) by 41.5% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,327 shares of the biopharmaceutical companys stock after selling 11,588 shares during the quarter. Squarepoint Ops LLC []